Identification of a Truncated Form of the G-protein Regulator AGS3 in Heart That Lacks the Tetratricopeptide Repeat Domains*

Nathalie PizzinatDagger, Aya Takesono§, and Stephen M. Lanier

From the Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425

Received for publication, August 18, 2000, and in revised form, December 21, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

AGS3, a 650-amino acid protein encoded by an ~4-kilobase (kb) mRNA enriched in rat brain, is a Galpha i/Galpha t-binding protein that competes with Gbeta gamma for interaction with Galpha GDP and acts as a guanine nucleotide dissociation inhibitor for heterotrimeric G-proteins. An ~2-kb AGS3 mRNA (AGS3-SHORT) is enriched in rat and human heart. We characterized the heart-enriched mRNA, identified the encoded protein, and determined its ability to interact with and regulate the guanine nucleotide-binding properties of G-proteins. Screening of a rat heart cDNA library, 5'-rapid amplification of cDNA ends, and RNase protection assays identified two populations of cDNAs (1979 and 2134 nucleotides plus the polyadenylation site) that diverged from the larger 4-kb mRNA (AGS3-LONG) in the middle of the protein coding region. Transfection of COS-7 cells with AGS3-SHORT cDNAs resulted in the expression of a major immunoreactive AGS3 polypeptide (Mr ~ 23,000) with a translational start site at Met495 of AGS3-LONG. Immunoblots indicated the expression of the Mr ~ 23,000 polypeptide in rat heart. Glutathione S-transferase-AGS3-SHORT selectively interacted with the GDP-bound versus guanosine 5'-O-(3-thiotriphosphate) (GTPgamma S)-bound conformation of Galpha i2 and inhibited GTPgamma S binding to Galpha i2. Protein interaction assays with glutathione S-transferase-AGS3-SHORT and heart lysates indicated interaction of AGS3-SHORT with Galpha i1/2 and Galpha i3, but not Galpha s or Galpha q. Immunofluorescent imaging and subcellular fractionation following transient expression of AGS3-SHORT and AGS3-LONG in COS-7 and Chinese hamster ovary cells indicated distinct subcellular distributions of the two forms of AGS3. Thus, AGS3 exists as a short and long form, both of which apparently stabilize the GDP-bound conformation of Galpha i, but which differ in their tissue distribution and trafficking within the cell.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

G-proteins serve as primary transducers for propagation of signals initiated by the superfamily of G-protein-coupled receptors. The basal activity of such G-protein signaling systems varies among cell types and at different stages of development. Several factors influence the basal activity of these systems, including constitutively active receptors and the type or amount of G-proteins and downstream signaling molecules expressed in the cell as well as proteins that directly influence the activation state of G-protein independent of G-protein-coupled receptors. Such receptor-independent regulators of G-protein activity include RGS proteins, caveolins, GAP43, and AGS proteins (1-10). Such regulators may allow G-proteins to subserve cellular functions independent of the typical, seven-membrane span receptor motif. AGS1-3, which do not share any apparent conserved sequences, were identified in a functional screen as receptor-independent activators of G-protein signaling (5-10). AGS1 is a member of the Ras family of small G-proteins and apparently acts as a guanine nucleotide exchange factor to increase GTP binding to Galpha i/Galpha o (5). In contrast, AGS3 actually stabilizes the GDP-bound conformation of Galpha i, inhibits dissociation of GDP from Galpha i, and competes with Gbeta gamma for interaction with Galpha i (6, 8-10). Thus, AGS3 may function as a guanine nucleotide dissociation inhibitor for Galpha i proteins and/or serve as a binding partner for Galpha i independent of Gbeta gamma .

AGS3 (650 amino acids) is encoded by an ~4-kb1 mRNA enriched in brain (6). AGS3 has two distinct domains separated by a linker region in the middle of the protein. The amino-terminal half of the protein contains seven tetratricopeptide repeats (TPRs), whereas the carboxyl-terminal half of the protein contains four G-protein regulatory (GPR) motifs,2 each of which is capable of interacting with Galpha i. As part of a continuing effort to understand the overall role of AGS3 and related proteins in G-protein function, we defined the tissue distribution of AGS3 mRNA. RNA blot analysis actually revealed two major transcripts of ~2 and ~4 kb that were selectively enriched in heart and brain. Further analysis of the AGS3 mRNA species indicated that the two transcripts potentially encoded related but distinct AGS3 proteins. We report the identification of a short form of AGS3 (AGS3-SHORT, 166 amino acids) that is encoded by the ~2-kb heart-enriched mRNA. AGS3-SHORT lacks the TPR domains found in AGS3-LONG, but contains three complete GPR motifs and a portion of the fourth GPR motif found in AGS-LONG. GST-AGS3-SHORT selectively interacted with G-proteins in heart cell lysates and inhibited nucleotide exchange on purified Galpha i2. Immunofluorescent imaging of mammalian cells transiently expressing AGS3-SHORT or AGS3-LONG indicated distinct locations of the two forms of AGS3 within the cell. AGS3 thus exists as short and long forms that differ in their tissue distribution and trafficking within the cell.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [32P]UTP (800 Ci/mmol) was purchased from PerkinElmer Life Sciences. Tissue culture supplies were obtained from JRH Biosciences (Lenexa, KS). Acrylamide, bisacrylamide, protein assay kits, and SDS were purchased from Bio-Rad. Guanosine diphosphate was obtained from Roche Molecular Biochemicals. Polyvinylidene difluoride membranes were obtained from Pall Gelman Sciences (Ann Arbor, MI). Polyclonal Galpha i3 antisera generated against the carboxyl-terminal 10 amino acids was kindly provided by Dr. Thomas W. Gettys (Department of Medicine, Medical University of South Carolina) (12). Superscript II, LipofectAMINE, and the 5'-RACE kit were obtained from Life Technologies, Inc. Marathon-Ready cDNA and multiple-tissue blots for rat and human mRNAs were obtained from CLONTECH. Galpha i2, expressed in and purified from Sf9 cells, was kindly provided by Stephen G. Graber (Department of Pharmacology, West Virginia University School of Medicine) (13). All other materials were obtained as previously described (6, 14, 15).

RNA Blot Analysis-- Rat brain and heart RNAs were isolated from 220-g Harlan Sprague-Dawley rats by extraction with RNAzol (TEL-TEST, Inc.). Total RNA (50-70 µg) was electrophoresed on 3% formaldehyde-containing 1% agarose gel and transferred to a nylon membrane (Hybond-N, Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom) under vacuum. The membrane was baked for 2 h at 80 °C in a vacuum oven and prehybridized and hybridized in phosphate buffer containing 0.5 M Na2HPO4, pH 7.2, 1% bovine serum albumin, 7% SDS, and 1 mM EDTA as previously described (16). 32P-Labeled cDNA probes were generated by random priming using the MultiPrime kit (Amersham Pharmacia Biotech). Blots were hybridized with the probe for 12 h at 65 °C, and the membrane was washed twice (40 mM Na2HPO4, pH 7.2, 5% SDS, and 1 mM EDTA) at 65 °C and exposed to XAR-5 film for 2-4 days at -70 °C.

Library Screening-- A rat heart cDNA library (Uni-ZAP XR, lot 937512, Stratagene) was screened with a 32P-labeled 40-mer oligonucleotide probe (5'-GTGGCCCTACCATGCCTGATGAGGATTTCTTCAGCCTTAT-3') corresponding to sequence located 1695 nt 3' to the translational start codon of AGS3-LONG. Procedures for hybridization, phage propagation, and plasmid excision were performed as previously described (16) and in accordance with the manufacturer's instructions. Positive phagemids were excised from the Uni-ZAP XR vector, and the nucleotide sequence of the insert was determined in the DNA Sequencing Facility at the Medical University of South Carolina.

5'-RACE-- mRNA was isolated from rat heart ventricle using the Oligotex mRNA kit (QIAGEN Inc., Chatsworth, CA). First-strand cDNA was synthesized from 4 µg of mRNA by reverse transcription (3 units of Superscript II, 30 min, 42 °C) using a gene-specific primer (5'-TTGGGAGGATTTGGCTTAC-3') derived from the 3'-UTR. An anchor sequence was then added to the 5'-end of the cDNA using terminal transferase and dCTP, and the cDNA was amplified by polymerase chain reaction using anchoring primers (5'-CUACUACUACUAGGCCACGCCTCGACTAGTACGGGIIGGGIIGGGIIG-3' and 5'-CUACUACUACUAGGCCACGCGTCGACTAGTAC-3') and nested AGS3-specific primers (nucleotides from the translational start codon of AGS3-LONG: nt 1670, 5'-GTTGTTGAGGGTGATGCGAAGC-3'; nt 1539, 5'-TCTGTGGTGAAGCTGTTACAGAGGG-3'; nt 1509, 5'-GTAGCCTCAGCAGCCCCAGC-3'; and nt 1476, 5'-CAGGGGACAGCGTTGGTCATC-3') in accordance with the manufacturer's instructions. Several series of experiments were done to optimize the tailing step and conditions for cDNA amplification.

The identification of 5' termini was also addressed by a similar general strategy using Marathon-Ready cDNA (CLONTECH, CA) and forward anchoring primers (5'-CCATCCTAATACGACTCACTATAGGGC-3' and 5'-ACTCACTATAGGGCTCGAGCGGC-3') and reverse AGS3-specific primers (nt 225 3' to the translational stop codon of AGS3-LONG, CCCTCCCCATACAGCAGCTCTA-3'; and nt 1941 in the protein coding region of AGS3-LONG, 5'-TTAGCTGGCACCTGGCGGACAT-3'). After four and two rounds of amplification with nested primers for the dC-tailed cDNA (kit from Life Technologies, Inc.) and Marathon-Ready cDNA, respectively, the amplified products were electrophoresed on agarose gels, and membrane transfers were hybridized with a 32P-labeled oligonucleotide (nt 1421 in the protein coding region of AGS3-LONG, 5'-CCCCGTCCTCTGACGAGGAGTGTTTCTTCGATCTG-3'). Positive DNA fragments were eluted from the gel and subcloned into the TA cloning vector pCR-TOPO (Invitrogen, San Diego, CA). Bacterial colonies obtained from these transformants were again screened by hybridization with the same AGS3 oligonucleotide. Plasmids from positive colonies were purified, and the nucleotide sequence of the insert was determined in the DNA Sequencing Facility at the Medical University of South Carolina.

RNase Protection Assays-- Tissue and cellular mRNAs were isolated as described above. Riboprobes were labeled with [32P]UTP (800 Ci/mmol), and RNase protection assays were performed using the Ambion series of pre-made reagents as described (15). RNA probes were generated from fragments of AGS3-SHORT cDNAs that spanned the region of sequence divergence from AGS3-LONG, thus allowing the detection of both AGS3-LONG and AGS3-SHORT transcripts in the same sample simply based upon size differences. To generate constructs for probe generation, an AGS3-SHORT-1 cDNA obtained by 5'-RACE was isolated from pCR-TOPO by restriction with NaeI and EcoRI and subcloned into the EcoRI and SmaI sites of pBluescript SK. For AGS3-SHORT-2, the longest cDNA isolated by library screening was restricted with EcoRI and SmaI and subcloned into the EcoRI and SmaI sites of pSK.Bluescript. The vectors were linearized by XhoI, and 32P-labeled antisense riboprobes were made using T3 RNA polymerase. 1 µg of heart or brain mRNA or 0.5 µg of CHO total RNA was hybridized with probe for 12 h at 45 °C, followed by RNase A/RNase T1 digestion. Protected fragments were separated on an 8 M urea and 5% polyacrylamide gel and visualized by exposure to X-Omat film at -90 °C for 12-24 h. The respective insert and probe lengths for AGS3-SHORT-1 were 357 and 447 nt. The respective insert and probe lengths for AGS3-SHORT-2 were 230 and 319 nt. The sizes of the protected fragments resulting from annealing the AGS3-SHORT-1 and AGS3-SHORT-2 probes with AGS3-LONG would be 228 and 184 nt, respectively.

Cell Transfection and Tissue Fractionation-- CHO and COS-7 cells were grown in Ham's F-12 medium and Dulbecco's modified Eagle's medium, respectively, supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml), and Fungizone (0.25 µg/ml). For transient expression, CHO and COS-7 cells at 70-80% confluency (100-mm dish) were transfected with 10 µg of AGS3-LONG or AGS3-SHORT cDNA using 30 µl of LipofectAMINE. Cells were harvested after 48 h and resuspended in lysis buffer (5 mM Tris-HCl, 5 mM EDTA, 5 mM EGTA, pH 7.4, 1 mM phenylmethylsulfonyl, 0.2 µg/ml soybean trypsin inhibitor, and 10 µg/ml aprotinin) with a 26<FR><NU>3</NU><DE>8</DE></FR> gauge syringe. The samples were centrifuged at 100,000 × g for 30 min at 4 °C to generate a crude membrane pellet and a 100,000 × g supernatant that represents the cytosol. The crude membrane pellet was washed once with 4 volumes of membrane buffer. Rat heart or brain tissue was homogenized in lysis buffer using a Powergen 125 tissue disruptor (Fisher), followed by Dounce homogenization. The homogenate was centrifuged at 500 × g for 15 min at 4 °C, and the supernatant from this spin was then centrifuged at 100,000 × g for 30 min at 4 °C to generate a crude membrane pellet and a 100,000 × g supernatant that represents the cytosol. Protein concentrations were determined with a Bio-Rad protein assay. Aliquots of samples were added to Laemmli sample buffer and placed in a boiling water bath for 5 min prior to processing by SDS-polyacrylamide gel electrophoresis and immunoblotting as previously described (6). Three AGS3 peptides (PEP22 (Asp528-Gly550), PEP98 (Val625-Ser650), and PEP32 (Thr407---Ile436)) from different areas of AGS3-LONG were synthesized and conjugated for generation of rabbit polyclonal antisera in the Peptide Synthesis and Antibody Production Facility at the Medical University of South Carolina. Each of the antisera was affinity-purified prior to use.

Immunofluorescence Microscopy-- CHO and COS-7 cells were plated onto coverslips (18-mm round no. 1) precoated with 0.01% polylysine and transfected with AGS3-SHORT-1, AGS3-LONG, or AGS3-TPR in pcDNA3. The AGS3-TPR construct consisted of the first 454 amino acids of AGS3-LONG. AGS3-TPR was generated by PCR using primers 5'-GGGGATCCATGGAGGCCTCCTGTCTGG-3' (forward) and 5'-GGAATTCTTTAATCAGCACTGTCCAGTG-3' (reverse), in which amino acid codon 455 of AGS3-LONG was mutated to a stop codon. 48 h after transfection, cells were briefly washed with cell washing solution (CWS; 137 mM NaCl, 2.6 mM KCl, 1.8 mM KH2PO4, and 10 mM Na2HPO4) and fixed for 5 min in CWS containing 3% paraformaldehyde. Fixed cells were rinsed with CWS (3 × 3 ml/coverslip) and incubated with 25 mM NH4Cl in CWS for 10 min to quench free aldehyde groups. Fixed cells were incubated with 0.05% Triton X-100 for 5 min at room temperature and washed twice with CWS (3 ml/coverslip). The coverslips were then incubated with CWS containing 1% fetal bovine serum for 30 min at 24 °C, followed by incubation with a 1:100 dilution of affinity-purified AGS3 PEP22, PEP32, or PEP98 antibody in CWS for 14 h at 4 °C. Coverslips were washed three times with CWS (3 ml/coverslip) and incubated with secondary antibody (fluorescein isothiocyanate-conjugated donkey anti-rabbit antibody, 5 µg/ml) for 60 min at 24 °C. Coverslips were washed three times (3 ml/coverslip) and mounted with Slow-Fade anti-fade reagent (ICN). A Leica DMLB fluorescence microscope and an Olympus confocal fluorescence microscope (FV5-PSU laser, BX50) were used for immunofluorescent microscopy. The cell nucleus was identified by propidium iodide staining. Multiple series of experiments (different fixation procedures, incubation times, and amounts of antibody) were performed to determine the optimal conditions for signal detection and to verify the specificity of observed signals. No immunofluorescent signal was detected in control cells transfected with the pcDNA3 control vector or in the absence of primary antibody. Each field of cells evaluated by microscopy contained both transfected and non-transfected cells, providing additional internal controls for observed signals.

Protein Interaction Assays-- The binding of AGS3-SHORT to G-proteins was assessed by protein interaction experiments using both rat heart lysates and purified Galpha i2. The AGS3-SHORT sequence encoding the Mr ~ 23,000 peptide was amplified by polymerase chain reaction and fused in frame to glutathione S-transferase in the pGEX-4T vector (Promega, Madison, WI). The GST-AGS3-SHORT fusion protein was expressed in bacteria (Escherichia coli BL21, Amersham Pharmacia Biotech) and purified on a glutathione affinity matrix. The AGS3-SHORT fusion protein was eluted from the resin, and glutathione was removed by desalting as previously described (14) to allow a solution-phase interaction assay. Rat heart lysates were prepared by Dounce homogenization in buffer (5 ml/heart) containing 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and 1 mM phenylmethylsulfonyl fluoride. The homogenates were gently rotated for 1 h on ice at 4 °C and then centrifuged at 27,000 × g for 30 min. Supernatants were collected and spun at 100,000 × g for 30 min to generate a detergent-soluble fraction.

For protein interaction studies with purified G-protein, GST or GST-AGS3-SHORT-1 fusion proteins (300 nM) were incubated with 100 nM Galpha i2 (preincubated with 10 µM GDP or GTPgamma S and 10 mM MgCl2 for 10 min at 4 °C) in 250 µl of incubation buffer (20 mM Tris-HCl, pH 7.4, 0.6 mM EDTA, 1 mM dithiothreitol, 70 mM NaCl, 0.01% Lubrol, 10 µM GDP or GTPgamma S, and 10 mM MgCl2) for 3 h at 4 °C with gentle rotation. 30 µl of a 50% slurry of glutathione-Sepharose was added, and incubation was continued at 4 °C for 40 min. Samples were then centrifuged, and the matrix was washed with 3 × 250 µl of incubation buffer prior to solubilization in Laemmli sample buffer. For interaction assays with tissue lysates, GST-AGS3-SHORT (5 µg) was incubated with 1-2 mg of lysate protein in buffer containing 50 mM Tris, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and 10 µM GDP for 12 h at 4 °C in a total volume of 250 µl. 25 µl of a 50% slurry of glutathione-Sepharose was added, and the mixture was rotated at 4 °C for 40 min, after which the affinity matrix was pelleted and washed three times with 500 µl of incubation buffer. Proteins retained on the matrix were solubilized in Laemmli sample buffer. Solubilized samples were electrophoresed on denaturing 10% polyacrylamide gels, and proteins were transferred to polyvinylidene difluoride membranes for immunoblotting with Galpha antisera. For reprobing of membranes, the membrane transfers were washed with immunoblot buffer containing 20 mM Tris-HCl, pH 7.6, 140 mM NaCl, and 0.2% Tween and then incubated with preheated stripping buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM beta -mercaptoethanol) for 20 min in a 55 °C water bath with gentle shaking. The membrane was washed with immunoblot buffer and processed for immunoblotting. Each blot was also incubated with AGS3 antisera and stained with Amido Black to provide internal controls for protein loading.

Nucleotide Binding Assays-- GTPgamma S binding assays were generally conducted as described (8, 9). G-proteins (100 nM) were preincubated for 20 min at 24 °C in the presence and absence of increasing concentrations of GST or GST-AGS3-SHORT. Reactions were initiated by addition of 0.5 µM [35S]GTPgamma S (4 × 104 dpm/pmol), and incubations (total volume of 50 µl) were continued for 30 min at 24 °C. Both preincubations and GTPgamma S binding assays were conducted in binding buffer containing 50 mM Hepes-HCl, pH 7.5, 1 mM EDTA, 1 mM dithiothreitol, 2 mM MgCl2, 50 µM adenosine triphosphate, and 10 µg/ml bovine serum albumin. Reactions were terminated by rapid filtration through nitrocellulose filters with 3 × 4 ml of stop buffer (50 mM Tris-HCl, 5 mM MgCl2, and 1 mM EDTA, pH 7.4) at 4 °C. Radioactivity bound to the filters was determined by liquid scintillation spectrometry. Nonspecific binding was defined with 100 µM GTPgamma S.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Tissue Distribution of AGS3 mRNA-- AGS3 was initially defined as a 650-amino acid protein encoded by an ~4-kb cDNA (6). To determine the tissue distribution of the AGS3 mRNA, we performed mRNA blot analysis with two probes derived from the upstream and downstream regions of the ~4-kb mRNA coding region (Fig. 1A). Both probes identified an ~4-kb mRNA enriched in brain (Fig. 1B). The 3'-probe identified an additional ~2-kb mRNA enriched in heart (Fig. 1, B and C). The ~2-kb mRNA was also identified with hybridization probes derived from the 3'-UTR of the ~4-kb cDNA.3 The relative expression of the ~4- and ~2-kb AGS3 mRNAs in heart was developmentally regulated. In rat heart, the ~4-kb mRNA was enriched at birth, whereas the ~2-kb mRNA predominated in the adult rat (Fig. 1C). Within the adult rat heart, the ~2-kb mRNA was clearly enriched in ventricular tissue. Although a full-length human AGS3 cDNA is not available, we obtained a partial human AGS3 expressed sequence tag clone and used this sequence to perform a similar RNA blot analysis in human tissue (Fig. 2). The human AGS3 probe (344 nt) corresponded to the same region of AGS3 used to generate PROBE B in Fig. 1 and thus would detect both AGS3-SHORT and AGS3-LONG. In human, as in rat, there were two AGS3 transcripts of ~2 and 4 kb that were differentially enriched in heart and brain (Fig. 2). As in rat heart, the ~4-kb AGS3 mRNA in human heart predominated at birth, whereas both mRNAs were expressed in the adult heart (Fig. 2). The ~4-kb mRNA and its encoded protein were termed AGS3-LONG, whereas the ~2-kb mRNA was termed AGS3-SHORT, and we initiated experiments to define the smaller mRNA and its encoded protein.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 1.   Tissue distribution of rat AGS3 mRNA. RNA blots in B and C were hybridized with radiolabeled probe derived from different regions of AGS3 as indicated in the schematic representation of AGS3 in A. The hatched and solid bars within the AGS3 coding region correspond to TPR and GPR motifs, respectively. B, CLONTECH multiple-tissue blot from rat containing 2 µg of poly(A)+ RNA/lane; C, 70 µg of total rat brain or heart RNA. Blots were stripped and hybridized with a random-primed probe from the coding region of rat beta -actin. ORF, open reading frame; bp, base pairs; sm, skeletal muscle. In C, atria and ventricle are from adult rat.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   Tissue distribution of human AGS3 mRNA. CLONTECH multiple-human tissue and cardiovascular system blots containing 2 µg of poly(A)+ RNA/lane were hybridized with a 344-nt probe generated from a partial human AGS3 cDNA (GenBankTM/EBI accession number AI272212; 2117 nt). The 344-nt probe corresponded to same region of AGS3 used to generate PROBE B in Fig. 1 and thus would detect both AGS3-SHORT and AGS3-LONG. Sm, skeletal muscle; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle. Blots were stripped and also hybridized with a random-primed probe from the coding region of rat beta -actin.

Identification of AGS3-SHORT cDNAs-- To define the AGS3-SHORT transcript, we screened a rat heart cDNA library, identified the 5' terminus by RACE, and performed RNase protection experiments. A rat heart cDNA library was screened with an oligonucleotide derived from the 3'-UTR of AGS3-LONG. 11 individual cDNAs were isolated and sequenced. The sizes of the cDNAs ranged from 1509 to 2134 nt, and each contained a 3'-UTR (~1.3 kb) identical to that of AGS3-LONG. Three identical cDNAs (AGS3-SHORT-1) contained 114 nt of 5'-terminal sequence that diverged from that of AGS3-LONG in the linker domain of the protein coding region of AGS3-LONG (Fig. 3). A fourth cDNA (AGS3-SHORT-2) contained 46 nt of 5'-terminal sequence that also diverged from that of AGS3-LONG in the linker region, and this 5'-sequence was distinct from that of AGS3-SHORT-1. The lengths of AGS3-SHORT-1 and AGS3-SHORT-2 cDNAs (1979 and 2134 nt plus the poly(A) tail) were similar to the size of the AGS3-SHORT mRNA identified by RNA blot analysis. The remaining cDNAs isolated from the rat heart library also terminated in the linker region, but did not diverge from the AGS3-LONG sequence, likely representing incomplete processing of the mRNA during reverse transcription.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   AGS3-SHORT cDNAs identified by library screening and 5'-RACE. Two populations of heart AGS3 cDNAs (AGS3-SHORT-1 and AGS3-SHORT-2) were identified as described under "Experimental Procedures." Uppercase letters indicate sequence identity to AGS3-LONG. The sequence unique to AGS3-SHORT cDNAs is indicated by lowercase letters. The arrows in the 3'-UTR and the coding region of AGS3-LONG indicate nested primers used for PCR amplification in 5'-RACE in the first and second experimental methods as described under "Experimental Procedures." The hatched and solid bars within the AGS3-LONG coding region correspond to TPR and GPR motifs, respectively. The stippled and striped segments of AGS3-SHORT cDNAs indicate sequence divergence from AGS3. The sequences of the unmarked open segment of AGS3-SHORT cDNAs and the 3'-UTR of AGS3-SHORT cDNAs were identical to those of AGS3-LONG.

To further define the population of AGS3-SHORT mRNAs in heart, we performed 5'-RACE by different methods with two different sources of rat heart mRNA. AGS3-SHORT-1 and AGS3-SHORT-2 were identified by 5'-RACE in both experimental methods. In the first method, mRNA was isolated from rat ventricles and reverse-transcribed with an AGS3-specific primer corresponding to sequence in the 3'-UTR of AGS3-LONG, and the AGS3-SHORT cDNAs were identified by library screening. The generated cDNAs were dC-tailed at the 5'-end and amplified with an anchor primer and a series of nested primers downstream from the 5' terminus of the AGS3-SHORT cDNAs identified by library screening. The second method involved a similar amplification strategy with different AGS3 nested primers, but used a commercial source of double-stranded cDNAs from rat heart as template. The two methods were selected to take advantage of the different 5'-tailing procedures and to evaluate different sources of mRNA. AGS3-SHORT-1 was represented by 11 of 14 cDNAs in the first method and by 10 of 18 cDNAs in the second method. The longest AGS3-SHORT-1 cDNAs identified by 5'-RACE contained 144 nt of 5'-terminal sequence that diverged from that of AGS3-LONG (Fig. 3). AGS3-SHORT-2 was identified (3 of 18) only in the second method. The remaining cDNAs (3 of 14 in the first method and 5 of 18 in the second method) contained various lengths of sequence that did not diverge from AGS3-LONG and likely represented incomplete extensions of the larger cDNA. Thus, AGS3-SHORT-1 and AGS3-SHORT-2 cDNAs were identified in three procedures using different sources of RNA and experimental strategies. In each case, AGS3-SHORT-1 cDNA was the predominant species.

Finally, we confirmed the expression of AGS3-SHORT cDNAs in heart by RNase protection assays using a probe design that allowed us to identify the AGS3-LONG and AGS3-SHORT cDNAs in the same reaction (Fig. 4A). To provide internal controls for observed signals, CHO cells were transiently transfected with AGS3-SHORT or AGS3-LONG cDNAs. As illustrated in Fig. 4B, RNase protection assays with the AGS3-SHORT-1 cDNA probe yielded two protected fragments in heart of ~350 and ~230 nt, corresponding to the predicted sizes of AGS3-SHORT-1 and AGS3-LONG (Fig. 4B), respectively. Due to the design of the AGS3-SHORT-1 probe, the signal in heart and brain actually represents the sum total of both AGS3-LONG and AGS3-SHORT-2 mRNAs. RNase protection assays with the AGS3-SHORT-2 cDNA probe (Fig. 4C) also yielded two protected fragments in heart and brain of ~230 and ~190 nt, corresponding to the predicted sizes of AGS3-SHORT-2 and AGS3-LONG, respectively. The two protected species corresponding to AGS3-SHORT and AGS3-LONG were the two major fragments detected in the assay, indicating the absence of any other heterogeneity in this region of the transcript. The two major protected species were also observed with both probes using brain RNA, although the AGS3-LONG fragment clearly predominated in brain tissue. Based upon the relative intensities of the AGS3-SHORT and AGS3-LONG protected species in Fig. 4 (B and C), it is also clear that the AGS3-SHORT-1 cDNA is the major AGS3-SHORT transcript, as suggested by the results obtained with library screening and 5'-RACE.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 4.   RNase protection experiments with probes derived from AGS3-SHORT cDNAs. A, the regions used to generate riboprobes for AGS3-SHORT cDNAs are indicated by the thick lines. The probes thus overlap the point at which the sequence of AGS3-SHORT cDNAs diverged from that of AGS3-LONG as described under "Experimental Procedures." Refer to the Fig. 3 legend for additional details. B and C, AGS3-SHORT cDNAs were inserted into pcDNA3 and transiently expressed in CHO cells as described under "Experimental Procedures" to provide internal controls. 1 µg of mRNA from brain or heart and 0.5 µg of total RNA from CHO transfectants were incubated with ~300,000 cpm AGS3-SHORT-1 (B) or AGS3-SHORT-2 (C) riboprobes at 45 °C for 12 h, and hybrids were treated with RNases, followed by precipitation. The pellets were resuspended in 20 µl of loading buffer and resolved on urea-5% polyacrylamide gels. 3 µl of the CHO transfectant samples and 10 µl of the tissue samples were loaded in B. 5 µl of the CHO transfectant, 5 µl of the brain samples, and 15 µl of the heart samples were loaded in C. In B, the AGS3-SHORT-1 cDNA used for CHO transfection actually lacked 15 nt at the 5'-end found in the AGS3-SHORT-1 RNA used for probe generation and thus resulted in the slightly smaller size observed with CHO versus heart RNA. In C, the AGS3-SHORT-2 cDNA used for CHO transfection and probe generation shared an extra 9 nucleotides from the vector, thus accounting for the slightly larger size observed with CHO versus heart RNA.

These data indicate that the AGS3-SHORT and AGS3-LONG transcripts contain identical 3'-UTRs and share a segment of the AGS3-LONG coding region, but differ in their 5' termini. The 5'-end of AGS3-SHORT mRNAs terminates in the linker domain of the protein coding region of AGS3-LONG and as such may encode a "truncated" version of the protein encoded by AGS3-LONG. This truncated version would be of particular interest as it would contain the GPR motifs that regulate Galpha i, but would lack the tetratricopeptide repeats found in the amino-terminal half of the protein.

Identification of the Protein Encoded by AGS3-SHORT cDNAs-- Analysis of the open reading frames for AGS3-SHORT cDNAs indicated that the longest open reading frame corresponded to the carboxyl-terminal third of the protein encoded by AGS3-LONG (Fig. 5) and that the divergent 5'-sequence of the AGS3-SHORT cDNAs was not in frame with the AGS3 protein coding sequence. For AGS3-SHORT-1, the major transcript in heart, the longest open reading frame began at nt 217, encoding a protein of 166 amino acids with a calculated Mr of 18,117. AGS3-SHORT-2 contains a slightly longer portion of AGS3-LONG at its 5'-end, and the longest open reading frame would begin at nt 189, encoding a protein of 227 amino acids with a calculated Mr of 25,076. The longest open reading frames for the AGS3-SHORT transcripts would initiate at methionines within the AGS3-LONG sequence itself. Neither of these methionines is placed in the context of an optimal Kozak consensus sequence for initiation of translation (17).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Open reading frame for AGS3-SHORT-1 and AGS3-SHORT-2. Uppercase letters indicate sequence identity to AGS3. The sequence unique to AGS3-SHORT cDNAs is indicated by lowercase letters. Amino acids are indicated beginning with the first ATG start codon in AGS3-SHORT cDNAs that is in frame with the AGS3-LONG protein coding sequence.

To define the encoded protein, we transiently expressed AGS3-SHORT cDNAs in COS-7 and CHO cells and performed immunoblot analysis with antisera generated against peptides derived from different regions of AGS3-LONG (Fig. 6A). PEP22 and PEP98 antisera would recognize AGS3-LONG and any AGS3-related proteins encoded by the AGS3-SHORT transcripts. PEP32 would recognize AGS3-LONG, but would not recognize any AGS3-related proteins encoded by the AGS3-SHORT-1 transcripts. The first in-frame methionine for AGS3-SHORT-2 is in the middle of the peptide sequence used to generate PEP32 and thus may or may not be recognized by PEP32 depending upon the epitope (Fig. 6A). Immunoblot analysis indicated that both AGS3-SHORT cDNAs encoded a major Mr ~ 23,000 polypeptide (Fig. 6B). The Mr ~ 23,000 peptide was not observed in immunoblots with PEP32 (Fig. 6B). The Mr ~ 23,000 peptide was not observed following transfection of COS-7 cells with pcDNA3-AGS3-SHORT-1M*, in which the first in-frame methionine was eliminated by site-directed mutagenesis (Fig. 6C). The start methionine for the Mr ~ 23,000 peptide corresponds to the first in-frame methionine for AGS3-SHORT-1 (nt 217) and the second in-frame methionine for AGS3-SHORT-2 (nt 372). Thus, the Mr ~ 23,000 peptide likely reflects translational initiation at the same methionine for both AGS3-SHORT cDNAs.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Transient expression of AGS3-SHORT cDNAs in COS-7 cells. A, schematic diagram indicating the locations of peptides used to generate AGS3 antisera. B, COS-7 cells were transfected with pcDNA3-AGS3-SHORT-1, pcDNA3-AGS3-SHORT-2, or pcDNA3-AGS3-LONG, and cells were harvested and processed 48 h later as described under "Experimental Procedures." P, 100,000 × g pellet; S, 100,000 × g supernatant. Membrane transfers were immunoblotted with antisera generated against AGS3 peptides derived from different regions of AGS3-LONG as indicated in A. LONG and SHORT-1 lanes, 15 µg of protein loaded for the pellet and supernatant; Vector and SHORT-2 lanes, 30 µg of protein loaded for the pellet and supernatant. The migration positions of size standards (×10-3; low molecular weight standards, Bio-Rad) are indicated between the panels. The arrowheads indicate the migration positions of immunoreactive AGS3 peptides. Data are representative of four independent experiments, and identical results were obtained with CHO transfectants. C, shown are site-directed mutations in putative translational start sites in AGS3-SHORT cDNAs. The first in-frame methionines for AGS3-SHORT cDNAs were disrupted by site-directed mutagenesis (ATG to GGG) and then transiently expressed in COS-7 cells as described under "Experimental Procedures." After 48 h, cells were harvested and processed to generate a 100,000 × g supernatant fraction for evaluation by SDS-polyacrylamide gel electrophoresis and immunoblotting with PEP22 antisera. SHORT-1 and SHORT-1M* lanes, 15 µg of protein loaded; Vector, SHORT-2, and SHORT-2M* lanes, 30 µg of protein loaded. Data are representative of two independent experiments using different batches of transfected cells. Refer to the Fig. 3 legend for additional details.

The AGS3-SHORT-2 cDNA also encoded two additional immunoreactive species (Mr ~ 32,000 and 34,000) upon COS-7 or CHO cell transfection. Both the Mr ~ 32,000 and 34,000 peptides were recognized by AGS3 PEP32, PEP22, and PEP98 antisera (Fig. 6B). The Mr ~ 32,000 peptide was not observed following transfection of COS-7 cells with pcDNA3-AGS3-SHORT-2M*, in which the first start methionine (nt 189) in frame with the AGS3 coding sequence was eliminated by site-directed mutagenesis (Fig. 6C). The immunoreactive signal for the Mr ~ 32,000 peptide was weaker than that for the Mr ~ 34,000 peptide, on the PEP32 immunoblot, which may reflect differences in the ability of the antibody to recognize the two proteins. As there are no additional in-frame codons for methionines upstream of nt 189, the Mr ~ 34,000 peptide must initiate at a non-AUG start codon in frame with the AGS3 protein coding sequence (18-20). The immunoreactive proteins expressed by AGS3-SHORT cDNAs in the transient transfection system were identical to those observed by in vitro translation using [35S]methionine to detect expressed proteins.3

As AGS3-SHORT mRNAs are enriched in heart, we then determined if these mRNAs were indeed translated. Rat heart tissue was fractionated to generate a post-nuclear crude membrane fraction and a 100,000 × g supernatant for analysis by immunoblotting with AGS3-specific antisera. A major Mr ~ 23,000 polypeptide was detected in heart by immunoblotting with either PEP22 (Fig. 7) or PEP98 antisera.3 The Mr ~ 23,000 immunoreactive species comigrated with the Mr ~ 23,000 peptide observed following transient expression of AGS3-SHORT cDNAs (Fig. 7). As observed for the Mr ~ 23,000 peptide expressed in COS-7 or CHO cells, the Mr ~ 23,000 immunoreactive peptide in heart was also enriched in the cytosol or 100,000 × g supernatant. In contrast to heart, the Mr ~ 72,000 peptide encoded by AGS3-LONG was the major immunoreactive peptide in brain. The Mr ~ 34,000 immunoreactive peptide in brain detected by PEP22 (Fig. 6) was not recognized by either PEP32 or PEP98 antibodies. The Mr ~ 32,000 and 34,000 peptides encoded by AGS3-SHORT-2 following transient transfection of COS-7 or CHO cells were not observed in heart (Fig. 6A). The lack of the larger Mr peptides likely reflects both the lower abundance of AGS3-SHORT-2 mRNA in heart as compared with AGS3-SHORT-1 mRNA as well as the preferential use of the second in-frame methionine (nt 372) as the translational start site in AGS3-SHORT-2 (Fig. 6B).


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 7.   Expression of AGS3-SHORT in heart. Tissues were homogenized and processed to generate crude membrane and cytosol fractions as described under "Experimental Procedures." P, 100,000 × g pellet; S, 100,000 × g supernatant. Internal controls for protein migration were generated by transient expression of AGS3-SHORT and AGS3-LONG cDNAs in COS-7 cells. Protein was loaded as follows: Heart and Brain lanes, 100 µg for the pellet and supernatant; AGS3-LONG lane (COS-7), 5 µg of protein; AGS3-SHORT-1 and AGS3-SHORT-2 lanes (COS-7), 10 and 20 µg of protein, respectively. The migration positions of size standards (×10-3; low molecular weight standards, Bio-Rad) are indicated to the right. Similar data were obtained in five separate experiments with different cell and tissue preparations.

Subcellular Distribution of AGS3-SHORT and AGS3-LONG-- Whereas AGS3-LONG contains seven TPR and four GPR motifs, AGS3-SHORT lacks TPR domains and contains 3.5 GPR motifs. The TPR regions of the Drosophila AGS3 homolog PINS play a key role in the positioning of the protein within the cell (21, 22). Thus, AGS3-SHORT and AGS3-LONG may follow different trafficking patterns within the cell. To more specifically address this issue, we performed immunofluorescent experiments to determine the subcellular location of AGS3-SHORT and AGS3-LONG following transient expression in COS-7 and CHO cells. Immunofluorescent analysis of AGS3 expression indicated clear differences in the subcellular distribution of the long and short AGS3 variants (Fig. 8). AGS3-SHORT was found throughout the cell, with a diffuse distribution in the cytosol. AGS3-LONG exhibited more of a punctate distribution, non-homogeneously distributed in the cell cytoplasm. The subcellular distribution of AGS3-TPR, which contained the first 454 amino acids of AGS3 and thus lacked the GPR domains, was identical to that of full-length AGS3-LONG. The subcellular distributions of AGS3-SHORT, AGS3-LONG, and AGS3-TPR were similar in both COS-7 and CHO cells. Another construct in which the AGS3-SHORT sequence was extended upstream to the carboxyl-terminal end of TPR-VII exhibited a subcellular distribution identical to that of AGS3-SHORT.3 These data indicate that the TPR domains indeed account for the differences in the targeting of AGS3-SHORT and AGS3-LONG within the cell.


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 8.   Immunofluorescent analysis of AGS3 distribution in mammalian cells. CHO (upper panels) and COS-7 (lower panels) cells were transfected with AGS3-SHORT-1, AGS3-LONG, or AGS3-TPR and processed as described under "Experimental Procedures." AGS3-SHORT and AGS3-LONG were detected with PEP22 antibody, whereas PEP32 antisera were used to detect AGS3-TPR. Each field of cells was evaluated by confocal microscopy at different planes of the cells, and the micrographs are images taken from approximately the middle plane of the cells. The large rounded area in the middle of the cell devoid of signal corresponds to the cell nucleus as defined by propidium iodide staining. This image was generated with an Olympus laser scanning confocal imaging system at a magnification of ×60. This figure is representative of images obtained in 5-10 different transfection experiments. No immunofluorescent signal was detected in the absence of primary antibody. Similar results were obtained with PEP98 antibody for AGS3-SHORT and with PEP98 and PEP32 antibodies for AGS3-LONG.

Multiple experiments in our laboratory are consistent with this point, particularly if one evaluates the relative distribution of the two forms of AGS3 in a 100,000 × g pellet and supernatant following cell lysis. Subcellular fractionation indicated that AGS3-SHORT readily partitioned into a 100,000 × g supernatant in rat heart and following transient expression in mammalian cells (Figs. 6 and 7). In contrast, AGS3-LONG was found in both the 100,000 × g pellet and supernatant following transient expression in mammalian cells. The relative distribution of AGS3-LONG in the 100,000 × g pellet versus supernatant was sensitive to the method of cell fractionation and varied in different cell types.3-5 Repeated washing of the 100,000 × g pellet releases the majority of AGS3-LONG into the supernatant, as observed for preparations from rat brain and primary cultures of cortical neurons and transfected cells (8).3-5 In contrast, essentially all of the AGS3-SHORT was found in the 100,000 × g supernatant independent of pellet washing. These data suggest a poorly understood, loose association of AGS3-LONG with a binding partner that retains AGS3-LONG in a different cellular compartment compared with AGS3-SHORT.

Interaction of AGS3-SHORT with G-proteins Results in Inhibition of Guanine Nucleotide Exchange and Movement of AGS3-SHORT to a Membrane Fraction-- To define the functional influence of AGS3-SHORT on G-protein, we first evaluated the interaction of AGS3-SHORT with purified Galpha i2. AGS3-SHORT was generated as a GST fusion protein and incubated with purified Galpha i2 in the presence of GDP or GTPgamma S. G-protein bound to AGS3-SHORT was isolated on a glutathione affinity matrix and identified by immunoblotting (Fig. 9A). AGS3-SHORT selectively interacted with the GDP-bound conformation of Galpha i2. These studies were then extended to determine the effect of AGS3-SHORT on the nucleotide-binding properties of Galpha i2. AGS3-SHORT effectively inhibited the binding of GTPgamma S to Galpha i2 (Fig. 9B), consistent with the idea that the interaction of AGS3-SHORT with Galpha i2 stabilizes the GDP-bound conformation of Galpha i. Further studies with rat heart lysates indicated a preference of AGS3-SHORT for the Gi family of proteins (Fig. 9C). GST-AGS3-SHORT bound Galpha i1/2 and Galpha i3, but not Galpha s, Galpha o, or Galpha q. Despite the presence of added GDP, which would stabilize the heterotrimeric G-protein complex, Gbeta gamma was not associated with the Galpha i bound to AGS3 (Fig. 9C).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 9.   Interaction of AGS3-SHORT with G-proteins. The region of AGS3-SHORT cDNA encoding the Mr ~ 23,000 immunoreactive peptide was generated as a GST fusion protein and used in protein interaction studies with purified Galpha i2 (A), guanine nucleotide binding assays with purified Galpha i2 (B), or protein interaction assays with heart lysates (C) as described under "Experimental Procedures." In B, data are presented as the mean ± S.E. from three experiments. In C, 2 mg of heart protein lysate was incubated with 5 µg of GST or GST-AGS3-SHORT fusion protein. AGS3-SHORT and proteins bound to AGS3-SHORT were isolated on a glutathione affinity matrix (10). Following gel electrophoresis of bound proteins, membrane transfers were probed with G-protein subunit antisera with intervening stripping of the blots as described under "Experimental Procedures." Experiments generating the data for A and C were repeated twice with identical results. The INPUT lanes in A and C contain one-twentieth of the lysate or purified Galpha i2 used in each individual interaction assay.

Although AGS3-SHORT and AGS3-LONG both bind Galpha i, the relative distribution of AGS3 and G-proteins within the cell differs, indicating that only a subpopulation of the two proteins may be complexed at any given time. A key question is what determines the subcellular location of AGS3 and if the trafficking of AGS3 is regulated by signals from inside or outside of the cell. As an initial approach to this issue, we investigated if coexpression of AGS3-SHORT or AGS3-LONG with Galpha i influenced the amount of AGS3 or Galpha i2 found in the 100,000 × g pellet following transient expression in COS-7 or CHO cells. Coexpression of AGS3-SHORT with Galpha i2 resulted in the movement of the AGS3-SHORT protein from the 100,000 × g supernatant to the 100,000 × g pellet (Fig. 10). The already substantial portion of AGS3-LONG found in the 100,000 × g pellet was not altered by coexpression of Galpha i2. In cells transfected with pcDNA3-Galpha i2, essentially all of the Galpha i2 protein was in the 100,000 × g pellet, and this was not altered by coexpression of AGS3-SHORT or AGS3-LONG.3 The translocation of AGS3-SHORT by Galpha i2 was specific, as there was only minimal translocation of AGS3-SHORT following overexpression of Galpha s (Fig. 10), which is consistent with the protein interaction experiments in which GST-AGS3-SHORT selectively bound Galpha i versus Galpha s in heart cell lysates (Fig. 10).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 10.   Influence of Galpha i2 and Galpha s on subcellular distribution of AGS3-SHORT and AGS3-LONG. COS-7 cells were transfected with pcDNA3 (Vector), pcDNA3-Galpha i2 (7.5 µg), pcDNA3-Galpha s (7.5 µg), pcDNA3-AGS3-SHORT-1 (2.5 µg), pcDNA3-AGS3-LONG (2.5 µg), or pcDNA3-G-protein plus pcDNA3, pcDNA3-AGS3-SHORT, or pcDNA3-AGS3-LONG. In each transfection, the total amount of plasmid used was 10 µg. Cells were harvested 48 h after transfection and processed as described under "Experimental Procedures." A 100,000 × g pellet and supernatant were prepared for each sample, and 20 µg of membrane protein was loaded in each lane. Membrane transfers were immunoblotted with PEP22 antisera. Blots were also stripped and reprobed with Galpha i and Galpha s antisera to confirm expression of the transfected Galpha protein. The migration positions of size standards (× 10-3; low molecular weight standards, Bio-Rad) are indicated to the left. Data are representative of four independent experiments.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The response of the cell to external stimuli has become progressively more intricate as higher organisms have evolved. Nature has certainly found the seven-membrane span motif along with its "partner" G-proteins to be one of the most efficient mechanisms for selective processing of spatially and temporally delineated signals by the cell. As the cell found itself challenged by a number of diverse stimuli, it evolved various mechanisms of integration to handle these inputs. The seven-membrane span motif has become more and more diverse in terms of the stimuli that it recognizes, and G-proteins have evolved by subunit diversification, differences in guanine nucleotide-binding/hydrolysis properties, and variations in post-translational modifications (23). Mechanisms for signal integration also include stoichiometric considerations, signal cross-talk, and spatial restriction of signaling components within the cell.

Additional specialized mechanisms for fine-tuning signal processing include receptor regulation and non-receptor proteins/lipids that influence subunit interactions and the activation state of G-proteins. Such entities include a number of proteins identified in protein interaction or functional screens. AGS3 is one of three proteins isolated as a G-protein regulator in a functional screen. This report indicates the expression of two forms of AGS3 (AGS3-SHORT and AGS3-LONG) that are differentially enriched in heart and brain. The two forms of AGS3 essentially differ in the presence and absence of the TPR domains found in the amino-terminal half of AGS3-LONG. The mechanism by which AGS3 is generated as two forms is unclear. Although the AGS3 (rat or human) gene is not defined, the AGS3-related protein in Caenorhabditis elegans is encoded by 14 exons (GenBankTM/EBI accession number U40409) (8). Thus, the two forms of AGS3 may be generated by alternative splicing, trans-splicing or even alternative promoters. Data base searches (BLAST) with the divergent 5'-ends of AGS3-SHORT cDNAs indicated no matches with AGS3-SHORT-2; however, the AGS3-SHORT-1-specific sequence was identical to a segment of the 5'-UTR of OMP25 (24). Whereas AGS3-LONG is the major species in adult rat brain, AGS3-SHORT is the major AGS3 protein expressed in adult rat heart. The relative expression of the two forms of AGS3 is developmentally regulated and apparently varies among the different regions of the heart.

At a structural level, the major differences between the short and long form of AGS3 are due to the absence in AGS3-SHORT of the seven TPR domains found in AGS3-LONG. This likely has important implications in terms of regulation of the function of AGS3-SHORT and AGS3-LONG. The TPR domain of the AGS3-LONG-related protein in Drosophila, PINS, is required for translocation of the protein to a specific membrane domain of the neuroblast, and this is achieved by the binding of the protein INSCUTEABLE to the TPR domains of PINS. The TPR motif is a highly degenerate sequence found in a large number of proteins, where it subserves various functions via protein interactions. The absence of the TPR motif in the AGS3-SHORT protein apparently accounts for the differences in subcellular distribution of the two forms of AGS3. The generation of two forms of AGS3 that apparently differ in subcellular trafficking and tissue distribution, but yet both interact with Galpha i subunits, is of particular interest. The two forms of AGS3 may play different roles in G-protein-regulated events.

AGS3-LONG in rat brain (8) and the AGS3-LONG-related protein PINS in Drosophila melanogaster (21, 22) are complexed with Galpha i, and AGS3-SHORT selectively interacts with Galpha i proteins in heart. The regions of AGS3 interacting with G-proteins are localized to the GPR motifs in the carboxyl-terminal half of the protein (6, 8), which are present in both AGS3-SHORT and AGS3-LONG. Each GPR motif in AGS3 appears capable of binding Galpha i(GDP) (8). Indeed, protein interaction experiments with a GST-AGS3 fusion protein containing four GPR motifs indicate that multiple Galpha i subunits may be tethered to AGS3, suggesting a role for the protein within a larger signal transduction complex (8). The interaction of AGS3 GPRs with Galpha i or Galpha t actually inhibits dissociation of GDP from Galpha i (8-10). The AGS3 GPRs also compete with Gbeta gamma for interaction with Galpha i (8). In the context of Gi heterotrimers, such an effect would lead to the generation of a Galpha i(GDP)·AGS3 complex with "release" of Gbeta gamma (6, 8). Indeed, in the protein interaction assays using heart lysates, Gbeta gamma subunits were not associated with the GST-AGS3-SHORT·Galpha i complex. The interaction of AGS3 with Galpha i/Galpha t may also play a regulatory role in G-protein activation by G-protein-coupled receptors. The GPR domains of AGS3 actually block rhodopsin activation of transducin and also prevent the interaction of Gi proteins with G-protein-coupled receptors (9, 10). Alternatively, the Galpha i(GDP)·AGS3 complex may exist independent of Gbeta gamma and subserve unique regulatory functions within the cell, where it might receive input from a putative guanine nucleotide exchange factor other than a G-protein-coupled receptor. AGS3 is actually just one of several proteins that regulate the activation state of G-protein independent of the receptor. Such proteins may be key players in signal integration and the dysfunctional signaling events observed in pathophysiological settings.

    ACKNOWLEDGEMENTS

We thank Mary Cismowski and Emir Duzic for their thoughts, suggestions, and encouragement. We thank John D. Hildebrandt (Medical University of South Carolina) for providing Galpha s, Galpha o, and Gbeta antisera; Thomas W. Gettys for Galpha i3 antisera; and Drs. Goldsmith, Shenkar, and Spiegel for Gq antibody. We thank Drs. George Lindenmayer and Robert Thompson (Medical University of South Carolina) for assistance with heart dissections. We thank Stephen G. Graber for purified Galpha i2 and Jane Jourdan for technical support.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants NS24821 and MH59931 (to S. M. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of a Medical University of South Carolina Health Sciences Foundation research fellowship and an Association de Recherche Contre le Cancer postdoctoral fellowship.

§ Supported in part by an Ikuei-Kai scholarship and a visiting graduate student from the Department of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

To whom correspondence should be addressed: Dept. of Pharmacology, Louisiana State University Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112. Tel.: 504-568-4740; Fax: 504-568-2361; E-mail:slanie@lsuhsc.edu.

Published, JBC Papers in Press, February 5, 2001, DOI 10.1074/jbc.M007573200

2 The GPR motif was also termed the GoLoco motif (11).

3 N. Pizzinat and S. M. Lanier, unpublished observations.

4 M. Bernard and S. M. Lanier, unpublished observations.

5 J. Blumer, S. M. Lanier, and J. Chandler, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: kb, kilobase(s); TPR, tetratricopeptide repeat; GPR, G-protein regulatory; GST, glutathione S-transferase; RACE, rapid amplification of cDNA ends; nt, nucleotide(s); UTR, untranslated region; CHO, Chinese hamster ovary; CWS, cell washing solution; GTPgamma S, guanosine 5'-O-(3-thiotriphosphate).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sato, M., Ribas, C., Hildebrandt, J. D., and Lanier, S. M. (1996) J. Biol. Chem. 271, 30052-30060[Abstract/Free Full Text]
2. Helper, J. R. (1999) Trends Pharmacol. Sci. 20, 376-382[CrossRef][Medline] [Order article via Infotrieve]
3. Okamoto, T., Schlegel, A., Scherer, P. E., and Lisanti, M. P. (1998) J. Biol. Chem. 273, 5419-5422[Free Full Text]
4. Strittmatter, S. M., Valenzuela, D., Kennedy, T. E., Neer, E. J., and Fishman, M. C. (1990) Nature 334, 836-841
5. Cismowski, M., Ma, C., Ribas, C., Xie, X., Spruyt, M., Lizano, J. S., Lanier, S. M., and Duzic, E. (2000) J. Biol. Chem. 275, 23421-23424[Abstract/Free Full Text]
6. Takesono, A., Cismowski, M. J., Ribas, C., Bernard, M., Chung, P., Hazard, S., III, Duzic, E., and Lanier, S. M. (1999) J. Biol. Chem. 274, 33202-33205[Abstract/Free Full Text]
7. Cismowski, M., Takesono, A., Ma, C., Lizano, J. S., Xie, S., Fuernkranz, H., Lanier, S. M., and Duzic, E. (1999) Nat. Biotechnol. 17, 878-883[CrossRef][Medline] [Order article via Infotrieve]
8. Bernard, M., Peterson, Y. K., Chung, P., Jourdan, J., and Lanier, S. M. (2001) J. Biol. Chem. 276, 1585-1593[Abstract/Free Full Text]
9. Peterson, Y. K., Bernard, M. L., Ma, H., Hazard, S., III, Graber, S. G., and Lanier, S. M. (2000) J. Biol. Chem. 275, 33193-33196[Abstract/Free Full Text]
10. Natochin, M., Lester, B., Peterson, Y. K., Bernard, M. L., Lanier, S. M., and Artemyev, N. O. (2000) J. Biol. Chem. 275, 40981-40985[Abstract/Free Full Text]
11. Siderovski, D. P., Diverse-Pierlussi, M. A., and De Vries, L. (1999) Trends Biochem. Sci. 24, 340-341[CrossRef][Medline] [Order article via Infotrieve]
12. Gettys, T. W., Fields, T. A., and Raymond, J. R. (1994) Biochemistry 33, 4283-4290[Medline] [Order article via Infotrieve]
13. Graber, S. G., Figler, R. A., and Garrison, J. C. (1992) J. Biol. Chem. 267, 1271-1278[Abstract/Free Full Text]
14. Wu, G., Hildebrandt, J., Benovic, J. L., and Lanier, S. M. (1998) J. Biol. Chem. 273, 7197-7200[Abstract/Free Full Text]
15. Saulnier-Blache, J. S., Yang, Q., Sherlock, J. D., and Lanier, S. M. (1996) Mol. Pharmacol. 50, 1432-1442[Abstract]
16. Lanier, S. M., Downing, S., Duzic, E., and Homcy, C. J. (1991) J. Biol. Chem. 266, 10470-10478[Abstract/Free Full Text]
17. Kozak, M. (1987) J. Mol. Biol. 196, 947-950[Medline] [Order article via Infotrieve]
18. Fuxe, J., Raschperger, E., and Pettersson, R. F. (2000) Oncogene 19, 1724-1728[CrossRef][Medline] [Order article via Infotrieve]
19. Arnaud, E., Touriol, C., Boutonnet, C., Gensac, M. C., Vagner, S., Prats, H., and Prats, A., C. (1999) Mol. Cell. Biol. 19, 505-514[Abstract/Free Full Text]
20. Kozak, M. (1997) EMBO J. 16, 2482-2492[Abstract/Free Full Text]
21. Yu, F. W., Morin, X., Cai, Y., Yang, X. H., and Chia, W. (2000) Cell 100, 399-409[Medline] [Order article via Infotrieve]
22. Schaefer, M., Schevchenko, A., Schevchenko, A., and Knoblich, J. A. (2000) Curr. Biol. 10, 353-362[CrossRef][Medline] [Order article via Infotrieve]
23. Hildebrandt, J. D. (1997) Biochem. Pharmacol. 54, 325-339[CrossRef][Medline] [Order article via Infotrieve]
24. Nemoto, Y., and DeCamilli, P. (1999) EMBO J. 18, 2991-3006[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.